Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.

Yu M, Yuan GY, Zhang B, Wu HY, Lv XF

Diabetes therapy : research, treatment and education of diabetes and related disorders10 Apr 2020Cited by 11 (Europe PMC)

PMID32277401PMCIDPMC7192976DOI10.1007/s13300-020-00804-2PepBankPUB-32277401

Read at source PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In AWARD-CHN1 Chinese patients with baseline HbA1c below 8.5%, HbA1c changed by -1.1% with dulaglutide 1.5 mg versus -0.7% with glimepiride.
In plain wordsIn Chinese patients with starting HbA1c below 8.5%, HbA1c fell by 1.1% with dulaglutide versus 0.7% with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN1 baseline below 8.5%
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1%
AWARD-CHN1 baseline HbA1c <8.5%, dulaglutide 1.5 mg
HbA1c change
−0.7%
AWARD-CHN1 baseline HbA1c <8.5%, glimepiride
Source sentences
Summary
In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.1% and - 2.2%; dulaglutide 0.75 mg: - 0.9% and - 2.0%; glimepiride: - 0.7% and - 1.4%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740101
02HumanNon-randomized trialEfficacy outcome
In AWARD-CHN1 Chinese patients with baseline HbA1c at least 8.5%, HbA1c changed by -2.2% with dulaglutide 1.5 mg versus -1.4% with glimepiride.
In plain wordsIn Chinese patients with starting HbA1c at least 8.5%, HbA1c fell by 2.2% with dulaglutide versus 1.4% with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN1 baseline at least 8.5%
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−2.2%
AWARD-CHN1 baseline HbA1c ≥8.5%, dulaglutide 1.5 mg
HbA1c change
−1.4%
AWARD-CHN1 baseline HbA1c ≥8.5%, glimepiride
Source sentences
Summary
In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.1% and - 2.2%; dulaglutide 0.75 mg: - 0.9% and - 2.0%; glimepiride: - 0.7% and - 1.4%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740102
03HumanNon-randomized trialEfficacy outcome
In AWARD-CHN1 Chinese patients with baseline HbA1c below 8.5%, HbA1c changed by -0.9% with dulaglutide 0.75 mg versus -0.7% with glimepiride.
In plain wordsIn Chinese patients with starting HbA1c below 8.5%, HbA1c fell by 0.9% with dulaglutide versus 0.7% with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN1 baseline below 8.5%
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.9%
AWARD-CHN1 baseline HbA1c <8.5%, dulaglutide 0.75 mg
HbA1c change
−0.7%
AWARD-CHN1 baseline HbA1c <8.5%, glimepiride
Source sentences
Summary
In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.1% and - 2.2%; dulaglutide 0.75 mg: - 0.9% and - 2.0%; glimepiride: - 0.7% and - 1.4%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740103
04HumanNon-randomized trialEfficacy outcome
In AWARD-CHN1 Chinese patients with baseline HbA1c at least 8.5%, HbA1c changed by -2.0% with dulaglutide 0.75 mg versus -1.4% with glimepiride.
In plain wordsIn Chinese patients with starting HbA1c at least 8.5%, HbA1c fell by 2.0% with dulaglutide versus 1.4% with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN1 baseline at least 8.5%
Study
n: not reported in source
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−2%
AWARD-CHN1 baseline HbA1c ≥8.5%, dulaglutide 0.75 mg
HbA1c change
−1.4%
AWARD-CHN1 baseline HbA1c ≥8.5%, glimepiride
Source sentences
Summary
In AWARD-CHN1, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.1% and - 2.2%; dulaglutide 0.75 mg: - 0.9% and - 2.0%; glimepiride: - 0.7% and - 1.4%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740104
05HumanNon-randomized trialEfficacy outcome
In AWARD-CHN2 Chinese patients with baseline HbA1c below 8.5%, HbA1c changed by -1.2% with dulaglutide 1.5 mg versus -0.6% with insulin glargine.
In plain wordsIn Chinese patients with starting HbA1c below 8.5%, HbA1c fell by 1.2% with dulaglutide versus 0.6% with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN2 baseline below 8.5%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2%
AWARD-CHN2 baseline HbA1c <8.5%, dulaglutide 1.5 mg
HbA1c change
−0.6%
AWARD-CHN2 baseline HbA1c <8.5%, insulin glargine
Source sentences
Summary
In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.2% and - 2.3%; dulaglutide 0.75 mg: - 1.0% and - 1.7%; and insulin glargine: - 0.6% and - 1.7%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740105
06HumanNon-randomized trialEfficacy outcome
In AWARD-CHN2 Chinese patients with baseline HbA1c at least 8.5%, HbA1c changed by -2.3% with dulaglutide 1.5 mg versus -1.7% with insulin glargine.
In plain wordsIn Chinese patients with starting HbA1c at least 8.5%, HbA1c fell by 2.3% with dulaglutide versus 1.7% with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN2 baseline at least 8.5%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−2.3%
AWARD-CHN2 baseline HbA1c ≥8.5%, dulaglutide 1.5 mg
HbA1c change
−1.7%
AWARD-CHN2 baseline HbA1c ≥8.5%, insulin glargine
Source sentences
Summary
In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.2% and - 2.3%; dulaglutide 0.75 mg: - 1.0% and - 1.7%; and insulin glargine: - 0.6% and - 1.7%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740106
07HumanNon-randomized trialEfficacy outcome
In AWARD-CHN2 Chinese patients with baseline HbA1c below 8.5%, HbA1c changed by -1.0% with dulaglutide 0.75 mg versus -0.6% with insulin glargine.
In plain wordsIn Chinese patients with starting HbA1c below 8.5%, HbA1c fell by 1.0% with dulaglutide versus 0.6% with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN2 baseline below 8.5%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
AWARD-CHN2 baseline HbA1c <8.5%, dulaglutide 0.75 mg
HbA1c change
−0.6%
AWARD-CHN2 baseline HbA1c <8.5%, insulin glargine
Source sentences
Summary
In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.2% and - 2.3%; dulaglutide 0.75 mg: - 1.0% and - 1.7%; and insulin glargine: - 0.6% and - 1.7%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740107
08HumanNon-randomized trialEfficacy outcome
In AWARD-CHN2 Chinese patients with baseline HbA1c at least 8.5%, HbA1c fell by 1.7% with dulaglutide 0.75 mg and by 1.7% with insulin glargine.
In plain wordsIn Chinese patients with starting HbA1c at least 8.5%, HbA1c fell by the same 1.7% with dulaglutide 0.75 mg and with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c, AWARD-CHN2 baseline at least 8.5%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.7%
AWARD-CHN2 baseline HbA1c ≥8.5%, dulaglutide 0.75 mg
HbA1c change
−1.7%
AWARD-CHN2 baseline HbA1c ≥8.5%, insulin glargine
Source sentences
Summary
In AWARD-CHN2, the HbA1c reductions at 26 weeks with baseline HbA1c < 8.5% and ≥ 8.5%, respectively, were dulaglutide 1.5 mg: - 1.2% and - 2.3%; dulaglutide 0.75 mg: - 1.0% and - 1.7%; and insulin glargine: - 0.6% and - 1.7%.
3 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740108
09HumanNon-randomized trialEfficacy outcome
In Chinese patients with T2DM, body weight decreased with both dulaglutide doses and increased with glimepiride or insulin glargine at 26 weeks, irrespective of baseline HbA1c.
In plain wordsIn Chinese patients with diabetes, weight fell with dulaglutide and rose with glimepiride or insulin glargine, whatever the starting HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight at 26 weeks
Study
n: not reported in source
Comparator
Glimepiride or insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg and 1.5 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
Irrespective of baseline HbA1c, body weight decreased with both dulaglutide doses and increased with either glimepiride or insulin glargine at 26 weeks.
4 context sentences(design, population, supporting numbers)
Summary · context
Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy.
Summary · context
AWARD-CHN2 (NCT01648582, n = 591) patients were on dulaglutide vs. insulin glargine and continued on metformin and/or sulfonylurea.
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740109
10HumanNon-randomized trialSafety outcome
In Chinese T2DM patients, hypoglycemia incidence was low with both dulaglutide doses in both trials.
In plain wordsIn Chinese patients with diabetes, low blood sugar incidence was low with both dulaglutide doses in both trials.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedHypoglycemia incidence in both trials
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide demonstrated low incidence of hypoglycemia in both doses in the two trials.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.
Summary · context
Post hoc analyses were conducted based on mixed-model repeated measures using a modified intent-to-treat analysis set with only the Chinese population.
Report a problemFND-3227740110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01644500

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 737Jul 2012 to Aug 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

CompletedPhase 3Results postedNCT01648582

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

Eli Lilly and Companyn = 774Jul 2012 to Dec 2014

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.